Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 10 19 9?
Displaying drugs 2051 - 2075 of 2649 in total
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. As of July...
Investigational
Matched Description: … 1500 participants to evaluate the vaccine’s protective effects on cancer patients from severe COVID-19
Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Investigational
Matched Iupac: … (2R)-1-{4-[(2R,4S,11R)-3,3-difluorotetracyclo[10.4.0.0^{2,4}.0^{5,10}]hexadeca-1(16),5,7,9,12,14-hexaen …
Etretinate is a medication used to treat severe psoriasis. It is a synthetic aromatic retinoid. The mechanism of action of etretinate is still incompletely understood although, like retinoic acid, it is thought to interfere with the terminal differentiation of keratinocytes. It is thought to bind to the retinoic acid receptors....
Withdrawn
Matched Iupac: … ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate …
A narcotic antagonist similar in action to naloxone. It is used to remobilize animals after etorphine neuroleptanalgesia and is considered a specific antagonist to etorphine. [PubChem]
Illicit
Vet approved
Matched Iupac: … (1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-(2-hydroxypropan-2-yl)-15-methoxy-13-oxa-3-azahexacyclo …
Matched Salts cas: … 16808-86-9
Experimental
Matched Iupac: … hydroxyethyl)-20-(propan-2-yloxy)-3,13-diazahexacyclo[14.8.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tetracosa-1(16
Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
Investigational
Investigational
Matched Iupac: … (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(1E)-1-(2-methyl-1,3-thiazol-4-yl)prop …
Ginkgolide A is a highly active PAF antagonist cage molecule that is isolated from the leaves of the Ginkgo biloba tree. Shows potential in a wide variety of inflammatory and immunological disorders.
Nutraceutical
Matched Iupac: … (1R,3R,6R,7S,8S,10R,11S,13S,16S,17R)-8-tert-butyl-6,17-dihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo …
An inhibitor of calcium-dependent isoforms of protein kinase C.[A253002,A253007]
Investigational
Matched Iupac: … 3-{23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tricosa-1(16) …
Perospirone is an atypical or second-generation antipsychotic of the azapirone family that antagonizes serotonin 5HT2A receptors and dopamine D2 receptors. It also displays affinity towards 5HT1A receptors as a partial agonist. Dainippon Sumitomo Pharma developed perospirone in Japan in 2001 for the treatment of acute schizophrenia and bipolar mania as...
Experimental
An NADPH oxidase 2 (NOX2) inhibitor.
Investigational
Matched Iupac: … 8lambda3-iodatricyclo[7.4.0.0^{2,7}]trideca-1(9),2,4,6,10,12-hexaen-8-ylium …
Matched Salts cas: … 3895-92-9
Palazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).
Investigational
Exatecan has been used in trials studying the treatment of Sarcoma, Leukemia, Lymphoma, Lung Cancer, and Liver Cancer, among others.
Investigational
Matched Iupac: … (10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.0^{2,14}.0 …
Matched Salts cas: … 197720-53-9
Experimental
Matched Iupac: … 2-(1,8-dihydroxy-9-oxo-9,10-dihydroanthracen-2-yl)acetic acid …
Experimental
Matched Iupac: … 5-[4-(9H-fluoren-9-yl)piperazine-1-carbonyl]-1H-indole …
Experimental
Matched Iupac: … 3-methoxy-4-[(piperidin-1-yl)methyl]-9H-xanthen-9-one …
Experimental
Matched Iupac: … 4-[(1S,4R,10S,13S,16S,18R)-10-{3-[(acetamidomethanimidoyl)amino]propyl}-18-hydroxy-16-[(1H-imidazol-4 …
Nutraceutical
Matched Iupac: … (1R,3R,6R,7S,8S,9R,10S,11S,13S,16S,17R)-8-tert-butyl-6,9,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo …
Nutraceutical
Matched Iupac: … (1S,3R,6R,7S,8S,9R,10S,11R,12R,13R,16S)-8-tert-butyl-6,9,12-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo …
CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.
Investigational
Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. The...
Experimental
Matched Description: … Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. …
A version of tabituximab barzuxetan radiolabeled with yttrium-90.
Investigational
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help...
Investigational
Matched Description: … 1500 participants to evaluate the vaccine’s protective effects on cancer patients from severe COVID-19
Displaying drugs 2051 - 2075 of 2649 in total